December 2017 | AIChE

Our websites use cookies to offer you a better browsing experience and analyze site traffic. By using our websites, you consent to our use of cookies.

Other Sites & Tools

Technical Groups

You are here

December 2017

Understanding and Reducing Risk as a STEM Student

December 27, 2017
December 28, 2017

Each of us can have a role in reducing risk, whether in our personal lives, in the community around us, or in the institutions where we study and work.

Reducing Risk

This series looks at risk from the perspective of various people in the community, showing how each individual can make informed decisions to balance risk instead of leaving thi

James Collins

Jim Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard.  He is one of the founders of the field of synthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics....Read more

David Schaffer

David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He graduated from Stanford University with a B.S. degree in Chemical Engineering in 1993. Afterward, he attended Massachusetts Institute of Technology and earned his Ph.D. also in Chemical Engineering in 1998 with Professor Doug Lauffenburger, while minoring in Molecular and Cell Biology. Finally, he conducted a postdoctoral fellowship in the laboratory of Fred Gage at the Salk...Read more

Clodagh O'Shea

Dr. O’Shea earned her bachelor’s degree in Biochemistry from University College Cork, Ireland. She did her doctorate in Immunology at the I.C.R.F. and Imperial College London, revealing key signals that regulate the development of our immune systems. After her graduate studies, she was selected for a Raleigh International expedition to Namibia where she worked on environmental, conservation and development projects. She did her postdoctoral research in Dr. Frank McCormick’s lab at UCSF on the prototype for oncolytic viral cancer therapy, ONYX-015. ...Read more

Alexander Marson

Alex Marson completed medical school at Harvard, PhD training at the Whitehead Institute/MIT with Richard Young and Rudolf Jaenisch, Internal Medicine residency at the Brigham and Women’s and clinical training in Infectious Diseases at UCSF.Read more

Susumu Tonegawa

Susumu Tonegawa received his Ph.D. from UCSD. He then undertook postdoctoral work at the Salk Institute in San Diego, before working at the Basel Institute for Immunology in Basel, Switzerland, where he performed his landmark immunology experiments. Tonegawa won the Nobel Prize for Physiology or Medicine in 1987 for “his discovery of the genetic principle for generation of antibody diversity.” He has since continued to make important contributions but in an entirely different field: neuroscience.

Using advanced techniques of gene manipulation, Tonegawa is now unraveling the...Read more

Crystal Mackall

Crystal L Mackall MD is Professor of Pediatrics and Medicine at Stanford University. She is Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, and Director of the Parker Institute for Cancer Immunotherapy at Stanford. During her tenure as Chief of the Pediatric Oncology Branch, NCI, she built an internationally recognized translational research program spanning basic studies of T cell homeostasis and tumor immunology, and clinical trials of immune based therapies for cancer. Her work is credited with identifying an essential...Read more

Introduction to special section on using pools to generate Good Laboratory Practice tox or other non - clinical material to accelerate development timelines

Accelerating patient access to novel biologics using stable pool - derived product for non - clinical studies and single clone - derived product for clinical studies

Pages